Animal study · rats

ARA-290 eased nerve-injury pain for up to 20 weeks in rats

Checked against the paper Animal studyPublished by PepVault

The takeaway

In rats, a short early course of ARA-290 after nerve injury was followed by reduced pain responses lasting up to 20 weeks.

Kind
Animal study
Studied in
Rats
Published
2014
Journal
Mol Pain

What they tested

The team tested whether different doses of ARA-290 reduce pain after a nerve injury in rats, and how it affects microglia and astrocytes, immune-type support cells in the spinal cord.

How the study was done

An animal study in rats given a spared nerve injury, treated with vehicle (an inactive carrier) or ARA-290 at 3, 10, 30 or 60 μg/kg on days 1, 3, 6, 8 and 10. Spinal cord tissue was examined at 2 or 20 weeks after injury or sham surgery.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking ARA-290? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In rats, ARA-290 lowered mechanical allodynia (pain from light touch) in a dose-related way for up to 20 weeks compared with vehicle. Cold allodynia was also reduced for up to 20 weeks at all four doses. At 2 weeks, vehicle-treated rats showed increased microglia activity in the L5 spinal segment while rats given 10 or 30 μg/kg did not; at 20 weeks only the 30 μg/kg group stayed free of increased microglia activity. Astrocyte reaction did not differ between groups.

What it doesn’t show

Every result comes from rats with a surgical nerve injury, and no people were tested. The calmer spinal microglia and the pain relief were seen together, which hints at a link but does not prove one causes the other.

The paper

Swartjes et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014.

The compound

More studies on ARA-290

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking ARA-290? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo